Just a few places remain for the annual GenesisCareUK SABR symposium in Leeds on Saturday 1 March🍿 Our prostate and spine workshops are FULL but there’s still time to secure a spot to hear our amazing keynote speakers: 💥 Dr. Nina Niu Sanford from UTSW on GI cancers, along with Mariam

81-year-old David Mather from Hale in Greater Manchester is one of the first people to be recruited to TOURIST, the world's largest clinical trial using radiotherapy to treat non-small cell lung cancer that has spread to other parts of the body. More 👉 bit.ly/3CJTJVP

A data-driven yet lyrical update from Tom Newsom-Davis on oncogene-driven lung cancer at the GenesisCareUK SABR symposium — ably chaired by Crispin Hiley

If you're at #BTOG25 today, we would love to see you to chat about the TOURIST #LungCancer platform #ClinicalTrial. Find our stand in the main exhibition hall, on the right as you walk in!

Poster presentations at #BTOG25 on our TOURIST #LungCancer and SELECTmeso #mesothelioma platform trials. We'll be at our stand in the main exhibition hall again today and tomorrow, so do come and have a chat about our #ClinicalTrials and working with SCTU!

Want to know more about reirradiation and its impact on cancer treatment? Join our expert-led webinar on Thurs 27 March to gain valuable insights, engage in live discussions, and enhance your expertise. 📢 Register now👉🏽 nuvi.me/buac5r

What a bonkers decision:’ Ridiculous’ cuts to AI cancer tech funding in England could cost lives, experts warn theguardian.com/politics/2025/…

It's been a fantastic start to April for the TOURIST Platform – PRINCE & QUARTZ LUNG Trials. 20 sites are now open to the TOURIST platform trial and we've already had patients being randomised to both arms of the trial this month. Well done to all the #research teams involved!

BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended Osimertinib with pemetrexed and platinum-based chemotherapy (based on the FLAURA2 trial) as an option for untreated advanced non-small-cell lung cancer (NSCLC) in adults whose

Another great milestone reached for the TOURIST platform #LungCancer trial. The PRINCE arm of the trial has now randomised 30 participants!! 👏🙌

1) Delighted to share our publication demonstrating the clinical effectiveness of prehabilitation in patients with lung cancer undergoing curative-intent radiotherapy. Largest cohort published to date in this under-studied area (outside of surgery). sciencedirect.com/science/articl…

Emerging Role of Targeted Therapies Combined with Radiotherapy in Inoperable Stage I-III, Non-Small Cell Lung Cancer (NSCLC): A Review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee.

MR-guided RT is a cornerstone of many of our clinical practices, and adaptive RT holds great potential to better serve our patients! Learn more here: redjournal.org/article/S0360-…

🚨 Job ad for excellent lung cancer & pleural fellowship 🫁 at Wythenshawe, Manchester (ideally post/peri-CCT)! Happy to discuss if there's questions

🔬 AVATAR trial published(ER+/HER2– MBC on AI + CDK4/6i): In OPD, SABR delayed therapy change (mPFS 9.9 mo) 🔷 44% on same Rx at 12 mo 🔷 36% at 24 mo Some received SABR 2–3× for new oligoprogressions—modified endpoints may better reflect its value. ascopubs.org/doi/10.1200/OA…

A great opportunity to work in cutting edge #clinicaltrials within a fun multidisciplinary team

That there isn’t! Come and join us for another amazing conference this year in this great city #radonc #medphys #rtt Gerry Hanna rebmuircab

Drew Moghanaki Shankar Siva Trans Tasman Radiation Oncology Group Similar, but different approach, used to ask this question in the UK PRINCE trial (n=400+). With David Woolf and many others. Oncologists in the UK please consider enrolling.

Crispin Hiley Shankar Siva Trans Tasman Radiation Oncology Group David Woolf Great to see QOL as the primary endpoint for PRINCE, and overall question about whether local therapy matters at all for these two cohorts. (I’m a big fan of the original QUARTZ phase III). cc Cecilia Pompili MD PhD FACS

It is an absolute pleasure to have been able to treat Jeff!